Loading...
We currently have vaccines that protect against meningococcal serotypes A, C, W-135, and Y. However, we lack a type B meningococcal vaccine that is sufficiently antigenic, especially in infants, for whom type B disease is particularly common. In a manufacturer-funded, phase 2b open-label trial, investigators in Europe tested a new, multicomponent serogroup B meningococcal vaccine (4CMenB). In a 2:2:1:1 ratio, 1885 infants were randomized to one of four groups:
4CMenB plus routine vaccines at ages 2, 4, and 6 months
4CMenB at ages 2, 4, and 6 months; plus routine vaccines at 3, 5, and 7 months
4CMenB plus routine vaccines at ages 2, 3, and 4 months
Routine vaccines alone at ages 2, 3, and 4 months
The primary outcome was a titer of ≥1:5 serum bac…